To appear in Best of the Brokers, email your research to email@example.com
Numis reiterated its “hold” recommendation, on the basis that Bloomsbury’s first-half results were “slightly below” expectations. The broker stated that the group had a “strong H2 pipeline” across its businesses and noted that it “continues to develop the Harry Potter portfolio”.
S&P Capital IQ raised its “hold” rating to “buy”, citing “positive corporate restructuring developments”. GlaxoSmithKline’s third-quarter results showed a decline in sales, although growth is predicted in the firm’s respiratory drugs range in 2016.